summary question: Is vaginal progesterone gel equivalent to vaginal micronized progesterone tablets concerning ongoing pregnancy rate and superior concerning patient convenience when used for luteal support after IVF/ICSI? summary answer: Equivalence of treatments in terms of ongoing live intrauterine pregnancy rate has not been demonstrated; the 95% confidence interval (CI) for the difference in ongoing pregnancy rate (28.2 to 0.1%) did not lie entirely within the pre-specified equivalence interval 27 to 7%.
Introduction
Luteal phase support is an essential aspect of assisted reproduction techniques (ARTs) . Previous studies have demonstrated that progesterone is superior to placebo and equally efficient as hCG for luteal support (van der Linden et al., 2011) . Although earlier studies found significantly higher pregnancy rates for i.m. compared with vaginal administration (Propst et al., 2001) , later studies (Yanushpolsky et al., 2011) and meta-analyses (Zarutskie et al., 2009; van der Linden et al., 2011) found comparable results. In one prospective study, although not randomized (Silverberg et al., 2012) , a higher live birth rate was found in the group receiving vaginal progesterone compared with the group receiving i.m. progesterone.
Moreover, vaginal progesterone was better tolerated than i.m. progesterone administration (Yanushpolsky et al., 2010) . Several other studies, including a recent meta-analysis (Polyzos et al., 2010) , have compared vaginal progesterone gel to other vaginal progesterone products and have found no significant differences in clinical pregnancy rates. However, all included studies were of limited size and none had sufficient power to determine whether there was any difference in clinical outcome between different compounds.
The aim of this large trial was to compare vaginal progesterone gel with vaginal micronized progesterone tablets in terms of ongoing pregnancy rates and patient convenience in patients undergoing IVF/ICSI.
Materials and Methods

Study design
This was a prospective, randomized, controlled multicentre trial performed in 18 fertility centres in Denmark and Sweden. Patients were recruited between March 2006 and January 2010 and randomized to one of two treatment groups: Vaginal progesterone gel (Crinone 8%, 90 mg, Merck Serono, Geneva, Switzerland) or vaginal micronized progesterone tablets [in Denmark Progestan, 200 mg, MSD, Ballerup, Denmark and in Sweden Progesteron MIC, 400 mg, Apoteksbolaget Produktion och Laboratorier (APL) Sweden]. The study was assessor blinded (blinded for treating physician and statistician). The primary objective of the study was to show equivalence in ongoing pregnancy rate at gestational week 7 between the two treatment groups. Ongoing pregnancy was defined as a sonographically verified intrauterine pregnancy, with a fetus with a heartbeat, 5 weeks after embryo transfer (gestational week 7). Secondary objectives were to show whether vaginal progesterone gel was superior to vaginal micronized progesterone tablets in terms of convenience and ease of use. Further secondary objectives were to compare positive pregnancy rates between groups, bleeding pattern before pregnancy test, implantation rate, live birth rate and multiple birth rates. The inclusion criteria were women ≥18 and ≤40 years of age, having regular menstrual cycles (25-35 days), presence of both ovaries and no more than two previous failed IVF attempts. The exclusion criteria were known drug abuse, allergies to the study medication, cancelled embryo transfer performed in the study cycle, embryo transfer not performed on Day 2 and previous participation in the study. The ethical committees of the participating centres approved the study and the patients signed informed consent. The study was performed in accordance with the Declaration of Helsinki and the ICH (International Conference on Harmonization) Harmonized Tripartite Guidelines for GCP.
Patients were randomized directly after embryo transfer, in a proportion of 1:1 into one of the two treatment groups. The patients had been down-regulated according to the long protocol with GnRH agonist (Synarela nasal spray, Pfizer, New York, NY, USA), 600 mg daily until the start of FSH stimulation, followed by 400 mg daily. Stimulation was performed with recombinant FSH (Gonal-f, Merck Serono, Geneva, Switzerland) according to the clinical routines of the different clinics. To trigger ovulation, recombinant hCG (rhCG), (Ovitrelle, Merck Serono) was used.
Luteal support commenced on the day of embryo transfer, Day 2 after oocyte retrieval, and was given for a total of 19 days (or until a negative pregnancy test). Vaginal progesterone gel was administered once daily. Vaginal micronized progesterone tablets were administered three times daily. Pregnancy was detected using a urinary or serum hCG test on Day 14 after embryo transfer. For patients having a positive pregnancy test, a vaginal sonography was performed 5 weeks after embryo transfer to establish whether the pregnancy was ongoing. A questionnaire regarding convenience and comfort was filled in on Day 14 after embryo transfer, before the pregnancy test. The questions included the following areas: ease of use, hygiene, interference with coitus, itching, burning, pain, leakage, time to administer the drug and overall impression.
Statistics
Patients were preliminarily recruited before starting the IVF cycle. If the patient fulfilled all the inclusion criteria and none of the exclusion criteria, the randomization took place on the day of embryo transfer after the transfer procedure. The study was designed to show equivalence in ongoing pregnancy rate between the two treatment groups. The true ongoing pregnancy rates in the two groups were assumed to be 0.30 and 0.32. The probability was 80% that the 95% confidence interval (CI) for difference in pregnancy rates between the groups was contained in the interval (20.07, 0.07) if 1343 patients were included in each group. The randomization protocol was a version of Pocock and Simon (1975) , often referred to as optimal allocation or minimization. The age of the woman (≤35 or .35 years) and the number of embryos transferred (1 or .1) were intended to be included as prognostic factors. A web-based randomization program was used with concealed allocation of patients. Descriptive statistics for continuous and categorical variables included mean, standard deviation, median, minimum and maximum and frequencies. For the primary end-point, a 95% CI for the difference in ongoing pregnancy rate between the groups was calculated. If the 95% CI was entirely within 20.07 to +0.07, equivalence between the treatments would be declared. The primary analysis was performed as a per protocol analysis. For secondary continuous end-points, analysis of covariance was used to detect differences between the groups. Covariates included were: age of the woman, number of embryos transferred, country and centre. For binary end-points, logistic regression or Cochran -Mantel -Haenszel was used with adjustments for age, number of embryos transferred, country and center. For each question in the patient questionnaire regarding convenience data proportional odds models were used. Adjustments were made for age group, number of embryos transferred, country and centre. Point estimate and 95% CI limits for the odds ratio were calculated. In case the assumptions of proportionality were not fulfilled, the Cochran-Mantel-Haenszel models were used. The variable overall impression was assessed as a score: 1 ¼ very convenient and 10 ¼ very inconvenient. Overall impression was analysed with analysis of covariance models including age, number of embryos transferred, country and centre. Least squares mean with a 95% CI were calculated.
All analyses on secondary end-points were performed on both the intention-to-treat and the per protocol populations. Sub-analysis per country was performed for all efficacy variables.
Error in randomization
Unfortunately, owing to data entry errors for the birth date of two patients used to calculate the age for the randomization, the resulting distribution of patients by age categories was very unbalanced. The age of the two patients having an error of data entry was calculated to be 1809 years and 1810 years. Both patients were in the vaginal progesterone gel arm of the study. Therefore, subsequent patients tended to be allocated to that arm if they were younger than the average, and to the vaginal micronized progesterone tablet arm if they were older. Two well-recognized and independent statisticians were contacted to give advice on how to manage this problem. Both statisticians came to the same conclusion: the results would be correct, provided that a stratified analysis with regard to age as a continuous variable was performed. The investigators followed this advice and the results are presented accordingly in this article.
Results
The trial was stopped after almost 4 years, owing to gradually falling recruitment, before the total estimated number of patients had been allocated. A total of 2662 patients fulfilling the initial inclusion criteria were recruited; 2057 patients were randomized and 1998 patients completed the study (Fig. 1) . Patient demographics are shown in Table I . Owing to the described error in the randomization procedure (see Statistics) mean age and age group differed significantly between the two groups. Otherwise, there were no significant differences in demographics between the groups.
Pregnancy and live birth
Ongoing intrauterine pregnancy, the primary end-point, was 30.2% (95% CI 27.3 -33.0%) in the vaginal progesterone gel group and 32.7% (29.7-35.6%) in the vaginal micronized progesterone tablet group. After adjustment for the woman's age and the number of embryos transferred, the difference in ongoing pregnancy rate between the groups was 24.1% (95% CI -8.2 to 0.1%). There was a significant difference in the proportion of positive pregnancy tests, 40.0% for vaginal progesterone gel versus 44.2% for vaginal micronized progesterone tablets (P ¼ 0.01). Implantation rate was 25.8% in the vaginal progesterone gel group and 26.8% in the vaginal micronized progesterone tablets group. The rate of miscarriage, 12.2% in the progesterone gel group and 15.9% in the micronized progesterone tablets group, did not differ significantly. The same applies to the live birth rate, 28.4% in the progesterone gel group and 30.1% in the micronized progesterone tablets group (Table III) .
Considering secondary end-points, the FSH starting dose was significantly lower in the progesterone gel group, [mean 167.2 standard deviation (SD) 54.3 IU versus 179.6 (SD 63.5) IU (P , 0.001)]. The number of embryos transferred did not differ between the groups, while the number of good-quality embryos transferred differed significantly [mean 0.8 (SD 0.6) in the progesterone gel group versus 0.9 (SD 0.6) in the micronized progesterone tablets group (P , 0.01)] (Table II) .
Patience convenience
The questionnaire showed that patient convenience and ease of use was in favour of vaginal progesterone gel in six out of nine questions: easy administration, hygiene, interference with coitus, leakage, time consumption and overall impression, while no significant differences were noted for itching, burning and pain (Fig. 2) . The overall impression about vaginal progesterone gel was 2.9 (2.7 -3.0) and of vaginal micronized progesterone tablets 4.8 (4.7 -5.0; P , 0.0001) (1 ¼ very convenient, 10 ¼ very inconvenient).
Bleeding pattern
A higher proportion of patients reported bleeding as well as more abundant bleeding before the pregnancy test in the progesterone gel group, 52.1 versus 38.0% (P , 0.0001). Among patients with bleeding, menstrual bleeding was reported by 44.7% in the progesterone gel group and 17.3% in the micronized progesterone tablets group (P , 0.0001), while more patients in the micronized progesterone tablets group reported spotting. However, when sonography was performed, there was no significant difference between the groups in terms of bleeding before pregnancy test among patients with an ongoing pregnancy [progesterone gel 9.4% and micronized progesterone tablets 11.5%, difference 22.1% (95% CI -6.9 to 2.7%)].
Adverse events
Most adverse and serious adverse events were unrelated to the study drug. Six adverse events were reported to be possibly related to the study medications; breast tenderness, rash, vulvo-vaginal pruritus, headache, fungal infection and fatigue.
Discussion
The main finding of this large multicenter trial was that equivalence of treatments in terms of ongoing live intrauterine pregnancy rate was not demonstrated. The 95% CI for the difference in ongoing pregnancy rate did not lie entirely within the pre-specified equivalence interval 27 to 7%. Although equivalence could not be declared, no substantial difference existed in the primary end-point, ongoing pregnancy rate, between vaginal progesterone gel and vaginal micronized progesterone tablets. After performing adjustment for age and number of embryos transferred, the difference in ongoing pregnancy rate between progesterone gel and micronized progesterone tablets was 24.1% (95% CI 28.2 to 0.1%). Previous studies comparing different vaginal progesterone treatments have included significantly fewer patients, resulting in less precise conclusions (Polyzos et al., 2010) . There is no doubt that luteal support following FSH stimulation in ART is essential (Pabuccu and Akar, 2005) . A successful pregnancy depends mainly on the following factors: age of the woman, ovarian reserve, embryo quality and synchronization between the embryo development and the endometrium. The supra-physiological steroid level accomplished after controlled ovarian stimulation and co-treatment with GnRH agonist or antagonist have both been discussed as deteriorating the luteal phase physiology (Macklon and Fauser, 2000) , necessitating luteal phase support with progesterone to secure the reproductive outcome. Many clinicians have expressed concern that there might be a significant difference in efficacy between the diverse forms of vaginally applied progesterone. It is therefore reassuring that the results, from this large trial, demonstrate no substantial difference in the number of ongoing pregnancies and no significant differences in miscarriage rate or live birth rate between the vaginal progesterone gel group and the vaginal micronized progesterone tablets group. A second finding of the present study was that vaginal progesterone gel was better tolerated by the patients. Not only ease of administration, hygiene, interference with coitus, leakage and time consumption, but particularly the overall impression was in favour of the vaginal progesterone gel. Better patient convenience for vaginal progesterone gel compared with intramuscularly administered progesterone was also reported in a recent study (Yanushpolsky et al., 2010) . Moreover, previous studies, although including a limited number of patients, reported vaginal progesterone gel to be superior to other vaginal progesterone products in terms of patient tolerability and ease of use (Ludwig et al., 2002; Ng et al., 2003; Simunic et al., 2007; Lan et al., 2008) .
More patients noted early bleeding, before the pregnancy test, in the progesterone gel group. However, of greater importance, among the patients having an ongoing pregnancy, bleeding was noted at a similar rate in the two groups, 9.4 and 11.5%, respectively. More bleeding, when using vaginal progesterone gel, has previously been reported in a study, comparing it with i.m. progesterone administration (Yanushpolsky et al., 2011) . In accordance with our results, early bleeding occurred at similar rates among patients with an ongoing pregnancy in both groups. Only the non-pregnant patients had a higher incidence of early bleeding when treated with vaginal progesterone gel.
This study highlights how a randomization error can affect the distribution of patients in a marked way. Computerized, web-based randomization is regarded as the most valid method of randomization, minimizing the risk of bias. In the present study, a web-based randomization program was used, with stratification for two variables: the age of the woman (≤35 or .35 years) and the number of embryos transferred (1 or .1). Owing to an error in the program, it was possible to enter the age of a patient incorrectly, which unfortunately occurred for two patients. The age of these two patients was entered in such a way that made it look much higher than their actual age. The randomization program tried to balance for these two incorrect ages, resulting in a skewed distribution of patients according to age. This error was discovered at the end of the study, when performing the analysis of the results. It seems natural, when performing clinical trials, to trust a randomization program. However, errors can take place and the lesson to be learnt from this study is to perform interim controls: not necessarily by interim analyses, but to check that the randomization has been performed correctly. If this had been done in the present study, the error would probably have been noticed earlier and the randomization program corrected.
In order to remedy the error as far as possible, we contacted two well-recognized and independent statisticians for advice on how to handle the problem. Both statisticians came to the same conclusion: the results should be correct provided that a stratified analysis regarding age as a continuous variable was performed. Another weakness of this trial was that the recruitment of patients was stopped prematurely, before the total estimated number of patients had been allocated. As such, the results should be viewed with some caution. In conclusion, equality of treatments in terms of ongoing pregnancy rates between vaginal progesterone gel and vaginal micronized progesterone tablets could not be demonstrated even though the results do not differ substantially. Vaginal progesterone gel provides a higher patient convenience. Finally, when performing clinical trials, one should be aware that errors in the randomization program may occur, which underlines the importance of adequate control systems.
